SMAD2 and colorectal cancer: Since inhibition of SMAD2/3 linker phosphorylation is proposed as a novel target for colorectal cancer therapy [13], we investigated the role and presence of pSMAD2L in NSCLC patients, cell lines as well as in primary cells, including AECII and T cells.